Nifty
Sensex
:
:
22828.55
75157.26
429.40 (1.92%)
1310.11 (1.77%)

Pharmaceuticals & Drugs - Domestic

Rating :
N/A

BSE: 506820 | NSE: ASTRAZEN

7599.00
06-Feb-2025
  • Open
  • High
  • Low
  • Previous Close
  •  7500.00
  •  7726.10
  •  7499.85
  •  7531.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  19590
  •  1491.71
  •  9059.05
  •  4800.15

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 21,193.75
  • 218.56
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 20,696.97
  • 0.28%
  • 29.84

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 75.00%
  • 1.33%
  • 14.62%
  • FII
  • DII
  • Others
  • 2.92%
  • 5.17%
  • 0.96%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.62
  • 9.27
  • 17.16

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 8.85
  • 16.44

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 17.47
  • 37.89

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 106.30
  • 107.09
  • 98.89

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 19.69
  • 19.76
  • 19.11

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 60.88
  • 64.28
  • 63.24

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
64.6
P/E Ratio
100.47
Revenue
1296
EBITDA
184
Net Income
162
ROA
15.7
P/B Ratio
22.79
ROE
24.84
FCFF
48.68
FCFF Yield
0.31

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated
Description
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Net Sales
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Expenses
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
EBITDA
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
EBIDTM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Other Income
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Interest
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Depreciation
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PBT
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Tax
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PAT
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PATM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
EPS
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

News Update:


  • AstraZeneca Pharma gets nod to import Osimertinib Tablets 40 mg & 80 mg
    5th Apr 2025, 15:52 PM

    The receipt of this permission paves way for the marketing of Osimertinib Tablets 40 mg & 80 mg in India for the specified additional indication

    Read More
  • AstraZeneca Pharma India gets nod to import, distribute Sodium Zirconium Cyclosilicate powder
    6th Mar 2025, 16:11 PM

    Through this approval, Sodium Zirconium Cyclosilicate is indicated for the treatment of hyperkalaemia in adult patients

    Read More
  • AstraZeneca Pharma India gets CDSCO’s nod to import, distribute Durvalumab solutions
    4th Mar 2025, 11:30 AM

    Durvalumab in combination with Tremelimumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma

    Read More
  • Astrazeneca Pharma I - Quarterly Results
    11th Feb 2025, 19:16 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.